Divi's Laboratories (NSE:DIVISLAB) Current Deferred Revenue: ₹0 Mil (As of Mar. 2026)


NSE:DIVISLAB Divi's Laboratories Ltd NSE:DIVISLAB
95 GF Score
Price ₹6,836.00
GF Value ₹6,779.51
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Divi's Laboratories Current Deferred Revenue?

Divi's Laboratories NSE:DIVISLAB +0.34% 95 Current Deferred Revenue is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 95/100 and a GF Value™ of ₹6,779.51 (Fairly Valued). The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Divi's Laboratories's current deferred revenue for the quarter that ended in Mar. 2026 was ₹0 Mil.

Divi's Laboratories Current Deferred Revenue Related Terms

Divi's Laboratories Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Divi's Laboratories's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Divi's Laboratories Current Deferred Revenue Chart

Divi's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Divi's Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:DIVISLAB
95GF Score
Divi's Laboratories Ltd NSE:DIVISLAB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0 Mil mean?
Divi's Laboratories (NSE:DIVISLAB) has a Current Deferred Revenue of ₹0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Divi's Laboratories and its competitors.
Is Divi's Laboratories' Current Deferred Revenue too high?
Divi's Laboratories' current Current Deferred Revenue is ₹0 Mil. Overall, Divi's Laboratories has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Current Deferred Revenue compare to ZTS and UTHR?
Divi's Laboratories' Current Deferred Revenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Divi's Laboratories and its competitors. Divi's Laboratories's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,779.51, compared to a current price of ₹6,836.00 — trading 0.8% above its estimated fair value. The current Current Deferred Revenue is ₹0 Mil. Divi's Laboratories' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Current Deferred Revenue is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued. The current stock price of ₹6,836.00 is trading 0.8% above its estimated GF Value™ of ₹6,779.51. GuruFocus considers Divi's Laboratories to be Fairly Valued.

Key valuation signals for NSE:DIVISLAB:

  • Current Deferred Revenue: ₹0 Mil
  • GF Value™: ₹6,779.51 vs. price of ₹6,836.00 (0.8% above fair value)
  • GF Score™: 95/100 with 6 warning signs

No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Divi's Laboratories Business Description

Other Exchanges 532488:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
95GF Score

Get the complete analysis for NSE:DIVISLAB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,836.00
Price
₹6,779.51
GF Value